NDA Reviews Will Be Risk-Based Under FDA’s GMP Initiative
This article was originally published in The Pink Sheet Daily
Executive Summary
The Center for Drug Evaluation & Research will apply a risk-based approach to manufacturing aspects of NDA review, Office of Compliance Director David Horowitz said
You may also be interested in...
Office Of New Drug Chemistry Reorganization Creates "PALS" For Industry
FDA's restructuring of the Office of New Drug Chemistry includes adding dedicated chemistry, manufacturing and controls reviewers within the premarketing and postmarketing divisions
Office Of New Drug Chemistry Reorganization Creates "PALS" For Industry
FDA's restructuring of the Office of New Drug Chemistry includes adding dedicated chemistry, manufacturing and controls reviewers within the premarketing and postmarketing divisions
FDA Good Manufacturing Practices Initiative Report Slated For October
GMP initiative report will include final guidance on process analytical technologies and aseptic processing, as well as draft guidance on the use of quality systems and computerized systems in clinical trials. The release will also contain "white paper" on prioritizing manufacturing sites for inspections.